{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016731","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.531984+00:00","generated_at":"2026-06-22T03:49:00.699363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Voyager Therapeutics reports Q3 net income $17.6M; Pfizer exercises TRACER capsid option","bullets":["Collaboration revenue $41.1M (vs $1.5M YoY) driven by $40M Pfizer option exercise recognition.","Net income $17.6M vs loss of $25.1M; cash $131.6M plus $10M Pfizer payment received in October.","Pfizer exercised option to license novel capsid; $10M payment, up to $290M in milestones plus tiered royalties.","Pipeline: lead development candidates for GBA1, SOD1, anti-tau programs expected Q4 2022 to H1 2023.","Novartis option decision on TRACER capsids for up to 5 targets expected by March 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016731","json":"https://secwatch.observer/filing/0001558370-22-016731.json","markdown":"https://secwatch.observer/filing/0001558370-22-016731.md","text":"https://secwatch.observer/filing/0001558370-22-016731.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000155837022016731/0001558370-22-016731-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000155837022016731/vygr-20221108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:49:00.699363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}